You are here
New Recommendations Issued by FDA for Ceftriaxone in Neonates
Based on the results from these studies, FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population. FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.
See the FDA Alert: Information for Healthcare Professionals - Ceftriaxone - FDA
Source: Food and Drug Administration